What do systematic reviews say?

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Sucrose (any concentration, any dose) vs glucose

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 94 participants
  Low
• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 94 participants
  Low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs breastfeeding

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 148 participants
  Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs breastfeeding

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 47 participants
  Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs expressed breast milk

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 88 participants
  Low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs expressed breast milk

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 88 participants
  Low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs expressed breast milk

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 88 participants
  Low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs expressed breast milk

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 35 participants
  Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs laser acupuncture

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs facilitated tucking

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 48 participants
  Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs facilitated tucking

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 48 participants
  Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs skin to skin care + water

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 151 participants
  Low
• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 111 participants
  Low
• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 154 participants
  Low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs skin to skin care + water

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 144 participants
  Low